IMRN Immuron Limited Stock Quote

IMRN [NASD]

Index	-	P/E	-	EPS (ttm)	-1.08	Insider Own	-	Shs Outstand	5.68M	Perf Week	0.73%
Market Cap	15.62M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	4.56M	Perf Month	-10.71%
Income	-	PEG	-	EPS next Q	-	Inst Own	2.69%	Short Float	0.05%	Perf Quarter	-4.84%
Sales	0.36M	P/S	43.83	EPS this Y	-	Inst Trans	-	Short Ratio	0.22	Perf Half Y	-16.67%
Book/sh	4.56	P/B	0.60	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-59.38%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	2.32 - 5.20	Perf YTD	10.00%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-47.12%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	18.53%	ATR	0.19
Employees	-	Current Ratio	-	Sales Q/Q	1037.30%	Oper. Margin	-	RSI (14)	44.79	Volatility	4.98% 6.88%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.16	Prev Close	2.74
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	9.93K	Price	2.75
Recom	2.00	SMA20	-3.57%	SMA50	-8.99%	SMA200	-22.79%	Volume	1,549	Change	0.36%

May-11-22 06:00AM	Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic GlobeNewswire
May-09-22 06:00AM	US Department of Defense Uniformed Services University Clinical Evaluation of Travelan GlobeNewswire
May-05-22 08:22PM	Immuron appoints Mr. Steven Lydeamore as Chief Executive Officer GlobeNewswire
Apr-27-22 06:00AM	Immuron Travelan® Global sales up 216% GlobeNewswire +5.19%
Apr-19-22 07:33AM	Immuron new MTEC project proposal Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease GlobeNewswire
Mar-25-22 05:21AM	We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate Simply Wall St.
Mar-16-22 09:30AM	Appointment of Paul Brennan as Non-Executive Director GlobeNewswire
Jan-17-22 06:00AM	Immuron Receives AUD $306,154 R&D Tax Concession Refund GlobeNewswire
Jan-13-22 06:00AM	Immuron Receives European Patent on Drug Composition to Treat Travelers Diarrhea GlobeNewswire -8.09%
Jan-12-22 02:58PM	IMRN Stock Alert: What Is the Huge Catalyst Sending Immuron Soaring? InvestorPlace +46.18%
07:28AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday InvestorPlace
06:34AM	Immuron stock rockets after funding by U.S. DoD of new research agreement MarketWatch
06:00AM	Immuron Receives A$6.2 Million Award from U.S. DoD to Clinically Evaluate a Military Strength Dosing Regimen for Travelan GlobeNewswire
04:59AM	Immuron Surges On U.S. DoD Funding For Travelan Research Investing.com
Nov-15-21 06:00AM	US DoD Uniformed Services University Travelers Diarrhea Clinical Update GlobeNewswire
Nov-10-21 06:00AM	US DoD Naval Medical Research Center Clinical Update GlobeNewswire
Oct-08-21 08:10AM	Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19 Benzinga +7.10%
07:34AM	18 Stocks Moving in Friday's Pre-Market Session Benzinga
06:00AM	IMM-124E Demonstrates Antiviral T-Cell Immunity GlobeNewswire
Sep-24-21 08:40PM	Companies Like Immuron (ASX:IMC) Are In A Position To Invest In Growth Simply Wall St. +9.64%
Sep-23-21 11:00PM	Immuron Director resignation GlobeNewswire -14.43%
09:00AM	Immuron planned Acquisition of R&D Vaccine Company GlobeNewswire
May-13-21 06:00AM	IMM124E May offer a New modality for Inhibition of SARS-CoV-2 GlobeNewswire
Mar-02-21 11:40AM	Immuron (ASX:IMC) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Jan-11-21 06:00AM	Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference GlobeNewswire
Dec-15-20 06:00AM	Immuron SARS-CoV-2 Research Agreement with Monash University GlobeNewswire +7.00%
Nov-24-20 06:00AM	Immuron Receives AUD $358,280 R&D Tax Concession Refund GlobeNewswire
Nov-11-20 06:00AM	US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine GlobeNewswire +24.44%
Oct-12-20 06:00AM	Immuron Travelers Diarrhea Market Update GlobeNewswire +9.25%

Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience